OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis $259.72 -7.90 (-2.95%) (As of 09/13/2024 08:54 PM ET) Add Compare Share Share Today's Range$257.15▼$268.1550-Day Range$250.03▼$282.9852-Week Range$241.09▼$390.30Volume1,600 shsAverage Volume1,267 shsMarket CapitalizationN/AP/E Ratio21.50Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Genmab A/S alerts: Email Address Ad DTII want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.Watch this URGENT training here! About Genmab A/S Stock (OTCMKTS:GNMSF)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GNMSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNMSF Stock News HeadlinesSeptember 16 at 4:44 AM | businesswire.comInvestigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1 ...September 11, 2024 | markets.businessinsider.comUBS Sticks to Their Buy Rating for Genmab A/S (0MGB)September 16, 2024 | DTI (Ad)I want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.August 27, 2024 | markets.businessinsider.comStrong Pipeline and Regulatory Approval Prospects Affirm Buy Rating for GenmabAugust 13, 2024 | msn.comGenmab A/S (NASDAQ:GMAB) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | seekingalpha.comGenmab A/S (GMAB) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | au.finance.yahoo.comGenmab A/S (GMAB.CO)August 5, 2024 | marketwatch.comGenmab Takes Control of Lung Cancer Drug Development After BioNTech Exits ProgramSeptember 16, 2024 | DTI (Ad)I want to be very real with youListen, I don’t come at my readers this direct very often, but here goes nothing: There is one strategy that has helped change my life and I’d like to think it has changed the lives of some of my readers, too. We’ve had success stories but I won’t even show you here because I don’t want you to get unrealistic expectations since individual results do vary. But the point is, this thing is the real deal. There’s a reason I consider it my flagship, even with all the market advantages I’ve discovered in recent years.July 19, 2024 | markets.businessinsider.comStrong Buy on Genmab: Robust DARZALEX Sales and Promising Pipeline Drive Positive OutlookJune 27, 2024 | investing.comGenmab A/S shares target raised on FDA approvalMay 20, 2024 | markets.businessinsider.comGenmab’s Buy Rating Affirmed by Promising Epcoritamab Trials and Regulatory MilestonesMay 20, 2024 | markets.businessinsider.comWhat 9 Analyst Ratings Have To Say About GenmabMay 14, 2024 | finance.yahoo.comDanish biotech says companies should tap into China’s ‘impressive innovation’May 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Genmab on Strong TIVDAK Approval and Promising Pipeline ValuationMay 1, 2024 | finance.yahoo.comComstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...April 16, 2024 | seekingalpha.comGenmab Acquires A Missing Piece For Its PipelineApril 16, 2024 | markets.businessinsider.comGenmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 BlnSee More Headlines Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:GNMSF CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees2,204Year Founded1999Profitability EPS (Most Recent Fiscal Year)$12.08 Trailing P/E Ratio21.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$631.91 million Net Margins29.06% Pretax Margin39.35% Return on Equity20.60% Return on Assets17.83% Debt Debt-to-Equity RatioN/A Current Ratio5.03 Quick Ratio5.02 Sales & Book Value Annual Sales$2.39 billion Price / SalesN/A Cash Flow$12.44 per share Price / Cash Flow20.87 Book Value$59.44 per share Price / Book4.37Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.07 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.91MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.03MMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.15MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $640.9kMr. Christopher Cozic (Age 45)Executive VP & Chief People Officer Comp: $786.56kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $699.16kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $116.53kDr. Judith V. Klimovsky M.D. (Age 66)Executive VP & Chief Development Officer Comp: $1.18MDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.12MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $160.22kMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW4D pharmaNASDAQ:LBPSW4Front VenturesOTCMKTS:FFNTFAbattis BioceuticalsOTCMKTS:ATTBFAeolus PharmaceuticalsOTCMKTS:AOLSView All Competitors GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed this year? Genmab A/S's stock was trading at $315.6999 at the beginning of 2024. Since then, GNMSF shares have decreased by 17.7% and is now trading at $259.72. View the best growth stocks for 2024 here. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) released its earnings results on Thursday, August, 8th. The company reported $3.13 earnings per share (EPS) for the quarter. The business had revenue of $779.50 million for the quarter. Genmab A/S had a trailing twelve-month return on equity of 20.60% and a net margin of 29.06%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNMSF) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
